Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 PillCam® Platform With the PillCam Crohn's Disease Capsule
Crohn's Disease
Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…
Phase 4 N=41 Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Otitis Media
Primary: Patency of the Tympanostomy Tube at the Day-14 Visit. — 8; 11; 15; 12 Ear — p=.36
Phase 4 N=30 Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
Cystic Fibrosis · Pneumonia · Pseudomonas Aeruginosa Infection
Primary: Population Pharmacokinetics - Total Body Clearance — 0.36 L/hr/kg
N/A N=92 Impact of Providing Free Preventive Dental Health Products on Infant's Tooth Brushing and Bottle-feeding Termination Practices
Infant's Tooth Brushing
Primary: Change in Mother's Reported Infant's Twice-a-day Tooth Brushing Practice. — 90.6; 10; 6.7 percentage of mothers
N/A N=42 Integrated Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)
Pain · Posttraumatic Stress Disorder
Primary: Clinician Administered Assessment of PTSD — 80.67; 70.83; 77.60; 74.73 units on a scale
Phase 3 N=325 Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Schizophrenia
Primary: Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6). — 91; 9 participants — p=<.0001
N/A N=72 Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method
Subcutaneous Adipose Tissue
Primary: Change in Waist Circumference 12 Weeks After Treatment as Compared to Baseline — -1.6; -.96; -1.4; -1.2 cm
Phase 2 N=25 A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
Pancreatic Cancer
Primary: Median Progression Free Survival — 10.1 weeks
N/A N=154 Preference Tiotropium Respimat Study in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Total Mean Score of the Validated Patient Satisfaction and Preference Questionnaire (PASAPQ) — 80.71; 79.92 units on a scale
N/A N=199 Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly
Lumbar Spondylosis · Cervical Spondylosis · Hip Osteoarthritis
Primary: Change in Neurocognitive Performance (Z-score) — .09; -.20; -.42; .01 z score
N/A N=81 Group Based Exposure Therapy for Combat-Related PTSD
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale (CAPS) — 82.4; 81.18; 71.73; 75.43 units on a scale
Phase 2 N=140 Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
Dentinal Hypersensitivity
Primary: Mean Change From Baseline in Schiff Sensitivity Score at Week 4 — 2.39; 2.41; 2.40; 2.38 Score on a scale — p=0.4321
N/A N=212 A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
Metastatic Renal Cell Carcinoma
Primary: Progression-Free Survival (PFS) From Initiation of Sutent Therapy
Phase 3 N=565 A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391